HSIC vs VYNE · P/E 24, rev $6.83B vs rev $501.0K
Henry Schein Inc (HSIC) versus Vyne Therapeutics Inc (VYNE) — a side-by-side from cached financials, not a winner call.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Vyne Therapeutics Inc (VYNE) is a biotechnology company listed on NASDAQ.
Latest reported HSIC revenue for 2026-06-27 was $6.83B. Net income was $201.0M. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Latest reported VYNE revenue for 2024-12-31 was $501.0K. Net income was -$39.8M. Revenue was up 18.2% from 2023-12-31 to 2024-12-31. VYNE currently screens at market cap $21.1M.
HSIC currently screens at market cap $9.11B and trailing P/E 24.2. VYNE currently screens at market cap $21.1M.
Not investment advice. Open the HSIC and VYNE stock pages for the full models.
Not investment advice.